Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 210-213

  Emsley, Robin ^a   Medori, Rossella ^b   Koen, Liezl ^a   Oosthuizen, Petrus Paulus ^a   Niehaus, Dana J H ^a   Rabinowitz, Jonathan ^c  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Janssen Cilag EMEA Belgium   (Belgium)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; ORPHENADRINE; PROLACTIN; PROPRANOLOL DERIVATIVE; RISPERIDONE;

ADOLESCENT; ADULT; AGGRESSION; AKATHISIA; AMENORRHEA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSTONIA; FEMALE; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; MALE; MUSCLE RIGIDITY; MUSCULOSKELETAL STIFFNESS; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS; LORAZEPAM; MALE; PILOT PROJECTS; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 41049103316     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318167269d     Document Type: Article

References (24)

1. Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv. 2004;55:997-1005.
2. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106:286-290.
3. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549.
4. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
5. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172:53-59.
6. Sheitman BB, Lee H, Strauss R, et al. The evaluation and treatment of first-episode psychosis. Schizophr Bull. 1997;23:653-661.
7. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry. 1995;152:1724-1729.
8. Strassnig M, Miewald J, Keshavan M, et al. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007;93:90-98.
9. International_Conference_on_Harmonization. ICH Harmonised Tripartite Guidelines for good clinical practice. Stat Med. 1999;18:1905-1942.
10. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P). New York, NY: New York State Psychiatric Institute, Biometrics Research; 1994.
11. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Rockville, MD: National Institute of Mental Health: US Department of Health Education and Welfare; 1976.
13. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;22:39-44.
14. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
15. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal symptom rating scale. Can J Neurol Sci. 1980;7:233.
16. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
17. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947-953.
18. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
19. Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin. 2006;22:241-255.
20. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
21. Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86:234-243.
22. Kopala LC, Good KP, Milliken H, et al. Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr Res. 2006;81:29-39.
23. Gaebel W, Riesbeck M, Wolwer W, et al. Maintenance treatment with risperidone or low dose haloperidol in first-episode schizophrenia: 1-year results of a randomised controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2007;68:1763-1774.
24. Remington G, Kwon J, Collins A, et al. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007;90:229-237.